AD
Adaptive Biotechnologies Corporation
ADPT · NASDAQ
$29.43 -1.77% (-$0.53)
1M +11.31%
Market Cap $4.46B
P/E Ratio -
Div. Yield -
ROE 32.64%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
0 /100
Expensive P/S 14.47x
P/B 31.20x
P/E N/A
Growth
66 /100
Stable Rev. growth 14.34%
Book val. growth 22.17%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 75.44%
FCF margin 7.80%
Net margin 20.73%
Quality
6 /100
Poor ROIC 6.67%
Asset turnover 0.48x
ROE 32.64%
Debt
23 /100
High Debt/Equity 2.87x
Int. coverage -2.79x
Current ratio 4.79x
Stability
14 /100
Unstable Beta 2.10x
Profitable years 0
Rev. volatility 33.16%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ADPT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Chad Robins
Employees
624
Headquarters
Seattle
Upcoming events
04 NOV
Earnings
Upcoming earnings report